Kura Oncology, Inc.
10.26-0.25 (-2.38%)
Oct 29, 4:00:02 PM EDT · NasdaqGS · KURA · USD
Key Stats
Market Cap
890.54MP/E (TTM)
-Basic EPS (TTM)
-2.25Dividend Yield
0%Recent Filings
8-K
Kura nets $30M milestone
Kura Oncology received a $30 million milestone payment from Kyowa Kirin on October 24, 2025, triggered by dosing the first patient in the KOMET-017 Phase 3 trials of ziftomenib, launched September 29, 2025. These global trials test the oral menin inhibitor with chemotherapy in newly diagnosed NPM1-mutated or KMT2A-rearranged AML patients. Cash bolsters development. Trials advance targeted therapy options.
8-K
Inducement plan expanded
Kura Oncology boosted its 2023 Inducement Option Plan on October 15, 2025, adding 750,000 shares to reach a total reserve of 3,250,000 common stock shares. This move, approved by the Board without shareholder vote under Nasdaq Rule 5635(c)(4), targets nonstatutory stock options for new hires not previously employed by the company. It signals aggressive talent acquisition in biotech. Yet dilution looms for existing shareholders.
8-K
Ziftomenib NDA under priority review
Kura Oncology reported Q2 2025 financials, highlighting FDA Priority Review for ziftomenib in relapsed/refractory NPM1-m AML with a PDUFA date of November 30, 2025. Collaboration revenue hit $15.3 million from Kyowa Kirin, yet R&D expenses surged to $62.8 million, driving a $66.1 million net loss. Cash stands at $630.7 million, funding operations into 2027 and ziftomenib commercialization. Phase 3 trials launch in 2H 2025.
10-Q
Q2 FY2025 results
Kura Oncology reported no revenue for Q2 FY2025 ended June 30, 2025, consistent with its clinical-stage focus, while advancing commercialization preparations through a co-promotion agreement with Kyowa Kirin signed June 27, 2025, for ziftomenib in the U.S. This deal positions Kura to lead U.S. commercialization, sharing costs and profits under a joint committee structure, with Kyowa Kirin handling 20-40% of detailing needs post-approval. Lease amendments extended office space at two San Diego locations through October 2025, supporting operational continuity without disclosed financial impact. Cash position stood strong at quarter-end, funding runway into late 2026. No operating or net income figures were detailed, but R&D expenses likely drove losses. Regulatory hurdles in oncology approvals pose ongoing risks.
8-K
Ziftomenib co-promotion pact
Kura Oncology inked a co-promotion deal with Kyowa Kirin US on June 27, 2025, to jointly push ziftomenib, its oral menin inhibitor for acute myeloid leukemia, in the US. Kyowa Kirin handles a slice of sales details while meeting minimum quotas; both split costs equally for promotion and medical affairs, where Kura leads but collaborates. This partnership bolsters commercialization under their November 2024 collaboration. The deal lasts until patent expiry or 10 years post-launch.
AURA
Aura Biosciences, Inc.
6.14-0.23
BBOT
BridgeBio Oncology Therapeutics
11.57+0.32
CRIS
Curis, Inc.
1.50+0.00
FATE
Fate Therapeutics, Inc.
1.34-0.15
KPTI
Karyopharm Therapeutics Inc.
6.08-0.28
LTRN
Lantern Pharma Inc.
3.82-0.16
MURA
Mural Oncology plc
2.10+0.01
NXTC
NextCure, Inc.
11.97+1.62
OKUR
OnKure Therapeutics, Inc.
3.19-0.14
ZURA
Zura Bio Limited
3.78+0.01